Technical Analysis for DMTK - DermTech, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical DMTK trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Expansion Breakdown | Bearish Swing Setup | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Buy Signal | Bullish | -13.74% | |
| NR7 | Range Contraction | -13.74% | |
| Inside Day | Range Contraction | -13.74% | |
| Wide Bands | Range Expansion | -13.74% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 1.5x Volume Pace | about 13 hours ago |
| Fell Below Lower Bollinger Band | about 14 hours ago |
| Lower Bollinger Band Support | about 15 hours ago |
| Down 1 ATR | about 15 hours ago |
| Trending on StockTwits | about 15 hours ago |
Get a Trading Sidekick!
- Earnings date: 03/04/2021
DermTech, Inc. Description
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Classification
Sector: Industrials
Industry: Conglomerates
Keywords: Medicine Cancer Melanoma Gene Expression Dermatology Diagnostic Tests Risk Assessment Pathology Biopsy Assessment Products Skin Cancer Melanoma Skin Cancer Pigmented Lesion Cutaneous Conditions
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 84.49 |
| 52 Week Low | 9.64 |
| Average Volume | 1,600,082 |
| 200-Day Moving Average | 26.92 |
| 50-Day Moving Average | 56.61 |
| 20-Day Moving Average | 48.54 |
| 10-Day Moving Average | 45.50 |
| Average True Range | 5.10 |
| ADX | 21.71 |
| +DI | 13.88 |
| -DI | 33.74 |
| Chandelier Exit (Long, 3 ATRs ) | 51.59 |
| Chandelier Exit (Short, 3 ATRs ) | 52.03 |
| Upper Bollinger Band | 59.99 |
| Lower Bollinger Band | 37.09 |
| Percent B (%b) | 0.02 |
| BandWidth | 47.17 |
| MACD Line | -3.67 |
| MACD Signal Line | -2.73 |
| MACD Histogram | -0.9341 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 46.66 | ||||
| Resistance 3 (R3) | 47.42 | 45.14 | 45.13 | ||
| Resistance 2 (R2) | 45.14 | 42.80 | 44.75 | 44.62 | |
| Resistance 1 (R1) | 41.31 | 41.36 | 40.17 | 40.55 | 44.11 |
| Pivot Point | 39.03 | 39.03 | 38.46 | 38.64 | 39.03 |
| Support 1 (S1) | 35.20 | 36.69 | 34.06 | 34.44 | 30.87 |
| Support 2 (S2) | 32.92 | 35.25 | 32.53 | 30.36 | |
| Support 3 (S3) | 29.09 | 32.92 | 29.85 | ||
| Support 4 (S4) | 28.33 |
